Bausch + Lomb Corp., a global eye health company, has bought AcuFocus Inc., a privately-held ophthalmic medical device company backed by KKR.
AcuFocus develops small aperture intraocular technology such as the IC-8 Apthera, which was approved by the U.S. FDA in July 2022 as a small aperture non-toric extended depth of focus (EDOF) intraocular lens implant (IOL) for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and want to address presbyopia at the same time. This IOL is available in select markets across Europe, Australia, New Zealand and Singapore.
We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb,” states Joseph Papa, CEO, Bausch + Lomb. “We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better.”
BofA Securities served as financial advisor to AcuFocus in this transaction. Norton Rose Fulbright US LLP served as legal advisor to Bausch + Lomb, and Latham & Watkins LLP served as legal advisor to AcuFocus.